CORCINCH-EU

About Ancora Heart

Ancora Heart is a private, clinical-stage medical device company pioneering a novel, minimally invasive approach to treating heart failure. Its lead product, the AccuCinch Ventricular Restoration System, is the first percutaneous device designed to directly remodel the dilated left ventricle, targeting the underlying structural pathology of HFrEF. The company is currently advancing the technology through the pivotal CORCINCH-HF study, a global randomized controlled trial. With FDA Breakthrough Device Designation, Ancora Heart is positioned to address a significant unmet need in a large, chronic patient population with high morbidity and mortality.

Therapeutic Areas